investor presentation kalbe farma

• Markets Data

Kalbe Farma Tbk PT

Select symbol.

• KLBF:JKT Indonesia Stock Exchange
• LCLA:BER Berlin Stock Exchange
• LCLA:MUN Munich Stock Exchange
• LCLA:DEU German Composite
• LCLA:STU Stuttgart Stock Exchange
• LCLA:FRA Frankfurt Stock Exchange
• United States
• PTKFF:PKL OTC Pink - Limited Information
• PTKFY:PKL OTC Pink - Limited Information
• Add to watchlist
• Add to portfolio
• Add an alert
• Price (IDR) 1,470.00
• Today's Change 15.00 / 1.03%
• Shares traded 20.83m
• 1 Year change -25.94%
• Beta 0.3797

Apply Cancel Actions

Your alerts done.

Profile data is unavailable for this security.

About the company

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of p roducts for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

• Revenue in IDR (TTM) 30.94tn
• Net income in IDR 2.87tn
• Incorporated 1967
• Employees 13.06k
• Location Kalbe Farma Tbk PT Gedung KALBE Let.Jend Suprato Kav. 4 JAKARTA PUSAT 10510 Indonesia IDN
• Phone +62 2 142873888
• Fax +62 214256326
• Website http://www.kalbe.co.id

Peer analysis

• Key Information
• Stock Performance
• Per Share Data
• Management Effectiveness
• Profitability
• Financial Strength
• Growth Rates

Institutional shareholders

• Top holders

Click or tap a row for details

trading higher

trading lower

Kalbe Farma Tbk PT

Key statistics.

2.60 mean rating - 10 analysts

2024 (millions IDR)

About Kalbe Farma Tbk PT (KLBF.JK)

Company information.

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

Contact Information

+ 62 ( 21 ) 42873888

http://www.kalbe.co.id

Biotechnology & Drugs

Executive Leadership

Income statement.

2023 (millions IDR)

Balance Sheet

Source: LSEG New Tab , opens new tab - data delayed by at least 15 minutes

Markets Performance

Commodities chevron.

Currencies Chevron

Rates & Bonds Chevron

Stocks Chevron

English (USA)

English (UK)

English (Canada)

English (India)

Deutsch (Deutschland)

Deutsch (Österreich)

Deutsch (Schweiz)

Français (France)

Français (Suisse)

Nederlands (Nederland)

Nederlands (België)

• Top Capitalization
• United States
• North America
• Middle East
• Sector Research
• Earnings Calendar
• Equities Analysis
• Most popular
• TESLA, INC.
• AMD (ADVANCED MICRO DEVICES)
• NIPPON ACTIVE VALUE FUND PLC
• VOLKSWAGEN AG
• NVIDIA CORPORATION
• AMAZON.COM, INC.
• Index Analysis
• Indexes News
• EURO STOXX 50
• Currency Cross Rate
• Currency Converter
• Forex Analysis
• Currencies News
• Precious metals
• Agriculture
• Industrial Metals
• Livestock and Cattle
• CRUDE OIL (WTI)
• CRUDE OIL (BRENT)

• Yield Curve
• Developed Nations
• Emerging Countries
• South America
• Analyst Reco.
• Capital Markets Transactions
• New Contracts
• Profit Warnings
• Appointments
• Press Releases
• Security Transactions
• Earnings reports
• New markets
• New products
• Corporate strategies
• Legal risks
• Share buybacks
• Mergers and acquisitions
• Call Transcripts
• Currency / Forex
• Commodities
• Cryptocurrencies
• Interest Rates
• Asset Management
• Climate and ESG
• Cybersecurity
• Geopolitics
• Central Banks
• Private Equity
• Business Leaders
• All our articles
• Most Read News
• All Analysis
• Satirical Cartoon
• Today's Editorial
• Crypto Recap
• Behind the numbers
• All our investments
• Asia, Pacific
• Virtual Portfolios
• USA Portfolio
• European Portfolio
• Asian Portfolio
• My previous session
• My most visited
• Dividend Aristocrats
• Growth stocks at reasonable prices
• Quality stocks
• Space Exploration
• E-Commerce & Logistics
• The food of tomorrow
• Oligopolies
• Unusual volumes
• New Historical Highs
• New Historical Lows
• Top Fundamentals
• Sales growth
• Earnings Growth
• Profitability
• Rankings Valuation
• Enterprise value
• Top Consensus
• Analyst Opinion
• Target price
• Estimates Revisions
• Top ranking ESG
• Environment
• Visibility Ranking
• Stock Screener Home
• Cloud Computing
• The genomic revolution
• Powerful brands
• Oversold stocks
• Overbought stocks
• Close to resistance
• Close to support
• Accumulation Phases
• Most volatile stocks
• Top Investor Rating
• Top Trading Rating
• Top Dividends
• Low valuations
• All my stocks
• Stock Screener
• Stock Screener PRO
• Portfolio Creator
• Event Screener
• Dynamic Chart
• Economic Calendar
• Our subscriptions
• Our Stock Picks
• Thematic Investment Lists

• Company PT Kalbe Farma Tbk.

ID1000125107

Pharmaceuticals.

Business Summary

Number of employees: 13,062

Sales per Business

Sales per region

Members of the board

Share class

Shareholders

Company contact information

PT Kalbe Farma Tbk

Gedung KALBE Jalan Let. Jend. Suprapto Kavling 4

10510, Jakarta

+62 21 4287 3888

Ratings for PT Kalbe Farma Tbk.

Analysts' consensus, eps revisions, quarterly earnings - rate of surprise, sector other pharmaceuticals.

• Stock Market

PT Kalbe Farma - Company Profile

All the data and insights you need on PT Kalbe Farma in one report.

Published: February 07, 2024 Report Code: CMT1610737-CP

• Share on Twitter
• Share on LinkedIn
• Share on Facebook
• Share on Threads
• Share via Email

Gain a 360-degree view of PT Kalbe Farma and make more informed decisions for your business.

Our PT Kalbe Farma Company Profile is a valuable source of information for anyone involved in:

Business Development

• Enhance your sales strategy and increase your chances of success
• Understand PT Kalbe Farma's position in the market and identify potential areas for collaboration
• Stay ahead of your competitors with valuable insights on mergers and acquisitions (M&A) activity, capital raising, and alliances and partnerships including legal and financial adviser associations
• Identify PT Kalbe Farma's key executives

Competitive Intelligence

• Understand PT Kalbe Farma's strategic initiatives and identify opportunities for growth and investment
• Get forward-looking insights from hiring trends, patenting activity, PT Kalbe Farma's innovation landscape, social media strategy and brand perception
• Support your decision-making with a management outlook on innovation, investments and IP risk exposure from earnings reports, investor presentations and ESG reports

Included in this Report:

What factors are shaping their future growth prospect?

Access detailed overview of company’s SWOT analysis and financial performance to understand its strengths, weaknesses, opportunities, and threats

What is their approach to key business areas

Gain a unique insight into company’s decision-making processes and how it compares with its peers

What is driving their success?

Get a better understanding of company’s competitive landscape, potential growth opportunities, and overall market positioning

What is their potential future performance?

Unlock a comprehensive ranking of companies based on their performance across 10 key industry themes

How are they leveraging digital technologies to drive growth?

Get valuable insights into company’s approach to digital transformation and their plans for leveraging digital technologies to achieve their business goals

Who are they hiring?

Stay informed on the latest developments in the company's talent acquisition strategy. Find out what skills and experience they are currently prioritising

What are their conversations and reputation in social media?

Learn how the company is using digital technologies to engage with customers and drive brand awareness. Understand its online reputation and customer sentiment

What is their position in the market?

Understand company’s position in the market and identify potential areas for collaboration

By purchasing the PT Kalbe Farma Company Profile you will access exclusive data from a trusted intelligence provider with decades of experience serving the most successful companies in the world.

Thousands of clients benefit from our trusted, actionable, and forward-looking intelligence every day. We help companies, government organisations and industry professionals profit from faster, more informed decisions.

PT Kalbe Farma company overview and more information about the report

Business strategy.

Unlock industry insights with our gold-standard data. Get an overview of PT Kalbe Farma's strategies within its core industry. Understand the market trends shaping the industry to gain a deep understanding of PT Kalbe Farma's strategic direction.

Financials and Ratios

Study PT Kalbe Farma's history, mission, products/services, target market and competition. Understand how the company operates in its industry and analyse its health with key financial statements including revenue, expenses, assets, liabilities and cash flow

Get an overview of PT Kalbe Farma's strategic plans with a geographical and thematic spread of M&A and investment strategy with corporate venturing and financial and legal adviser associations. Forward-looking Signals

CXO Insights

Insights from management, analyst sentiment and the divergence from earnings call transcripts. Furthermore, CXO priorities around investments, acquisitions, R&D, human capital, evolving risk exposures and geographic concerns help in understanding key strategic developments.

Competitive Benchmarking

Gain understanding on the PT Kalbe Farma market positioning compared to its key peers . for a comparative analysis of all key signals including deals, patents, hiring and social media. Also . track strategic developments, financial performance across the PT Kalbe Farma peers.

• Company Financials
• Research & Development
• SWOT Analysis
• Business Segments
• Corporate Strategy
• Key Executives
• Industry Exposure
• Locations & Subsidiaries
• Drugs by Therapy Area
• Drugs by Development Stage
• Drugs by Therapy Area and Development Stage
• Outsourcing Relationships
• Theme Exposure
• Technology Budget Estimates / ICT Budgets
• ICT Contracts / Software & Services Contracts
• Install Base
• Recent Partnerships
• M&A Strategy
• Capital Raising Strategy
• Strategic Alliances & Partnerships
• Advisor Strategy – Financial and Legal Advisors
• News Trend and Sentiment
• Product Development
• Business Expansion
• Recent News
• Patent Publication Trends
• Patents by Authority
• Patents & IP Protection by Country/Region
• Top Innovators
• Leader by Innovation & Disruptive Potential
• Recent Applications & Grants
• Filings Sentiment and Mentions
• "CXO Intent ( R&D Investment, Human Capital)"
• Filings Theme Exposure
• Mentions and Growth by Region
• Recent Filings
• Twitter Influencer Activity Trend
• Reddit Activity Trend
• Financial Ratios
• Deals Competitive Benchmarking
• Social Media & Ads Competitive Benchmarking

PT Kalbe Farma Company Profile

• Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
• USD - US Dollar
• AUD — Australian Dollar
• BRL — Brazilian Real
• CNY — Yuan Renminbi
• GBP — Pound Sterling
• INR — Indian Rupee
• JPY — Japanese Yen
• ZAR — South African Rand
• The Price Conversion is only for the Indicative purpose.
• USD — US Dollar
• RUB — Russian Ruble

About GlobalData

GlobalData is the trusted, gold standard intelligence provider to the world's largest industries.

We help thousands of companies, government organizations, and industry professionals profit from faster, more informed decisions.

Enquire Before Buying

Sample Report

PT Kalbe Farma Company Profile is the most comprehensive report available on the market and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample report to help you:

• Assess the relevance of the report
• Evaluate the quality of the report
• Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to help you understand the structure of the report you are buying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PT Kalbe Farma in real time.

• Get access to cross-sector data and analysis across 22 industries, 120+ sub-sectors and 1,400+ segments.
• Fuel your decision making with real-time deal coverage and media activity.
• Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

• Get 7 Days Free

PT Kalbe Farma Tbk KLBF

Sponsor center.

• Technology Vendors
• Recent Research
• Media Support

Founded Year

Date of ipo, stock price, about kalbe.

Kalbe (IDX: KLBF) operates as a pharmaceutical company. It provides research and development activities in generic drug formulation and the continuous development of consumer and nutritional products. The company offers drugs, capsules, syrup, and medicines for eye care, animal health, and nutritional uses. It was founded in 1966 and is based in Jakarta, Indonesia.

Headquarters Location

Jl. Let. Jend Suprapto Kav 4

Jakarta, 10510,

+60 322828507

Latest Kalbe News

Jun 20, 2024

News provided by Share this article Share toX GC Cell and PT Bifarma Adiluhung announced a strategic partnership to facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell therapy for HCC into the Indonesian market. YONGIN, South Korea, June 19, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell and gene therapy pioneer, is proud to announce the establishment of an MOU for strategic partnership with Bifarma , a frontrunner in stem cell therapy within Indonesia with comprehensive capabilities in R&D, GMP-compliant manufacturing, and the commercialization of cell therapies. This strategic partnership marks a significant step towards entering the Indonesian market and expanding into the innovative cell therapy sector, particularly to facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell therapy for liver cancer surgery in Korea. The MOU also includes discussions on technology transfer and broad cooperation on the development of additional NK cell therapy pipelines. Furthermore, GC Cell recently unveiled its Blueprint 2.0 strategy, emphasizing a company-wide strategic shift towards future growth drivers. A pivotal component of this strategy is the global market entry of its proprietary cell therapy products, Immuncell-LC, Korea's pioneering cell therapy, along with securing the foundation for NK cell therapy pipelines across the Asia-Pacific region. Indonesia, known for its large population and robust growth rate coupled with the advent of universal healthcare, presents a promising market for autologous cell therapies. Such therapies are increasingly accessible through medical procedures that are supported by substantial clinical data, similar to those in Japan. Through this strategic partnership with Bifarma and leveraging the Kalbe Group's extensive local infrastructure, including cold chain logistics and a broad hospital network, GC Cell anticipates the accelerated launch of its Immuncell-LC beyond Korea. James Park, CEO of GC Cell, commented, "This partnership is a testament to the global recognition of our cell therapy expertise, first established in Korea. By combining GC Cell's integrated value chain in cell and gene therapy with Bifarma's strong market presence and capabilities in Indonesia, we are poised to rapidly capture a leading position in the burgeoning field of anti-cancer cell therapies." "We are pleased to announce that Bifarma, through our cell therapy division ReGeniC, has entered into a MOU with GC Cell, a pioneering biopharmaceutical company from Korea. This strategic collaboration represents a significant milestone for both organizations and reinforces our mission to offer advanced, safe, and high-quality cell therapy," said Dr. Sandy Qlintang, MBiomed., President Director of PT Bifarma Adiluhung. This MOU represents a significant milestone for both organizations in their pursuit to transform patient care and fortify their positions in the global healthcare landscape. About GC Cell With a core focus on cell therapy, GC Cell offers complete bio healthcare solutions from diagnosis to treatment, and the brand's comprehensive value chain spans R&D, production, commercialization, and distribution. About PT Bifarma Adiluhung PT Bifarma Adiluhung, through its cell therapy division Regenic, is Indonesia's first and largest cell-based therapy provider, holding GMP certification from Indonesia's FDA and an operating license from Ministry of Health for clinical-grade manufacturing of stem cells and their metabolites. Regenic services encompass autologous and allogeneic stem cells and their derivatives, a stem cell education center, and an R&D center focused on innovative cell therapy products. Regenic is dedicated to advancing healthcare through pioneering cell-based therapies to enhance the quality of life for all individuals. About PT Kalbe Farma Tbk PT Kalbe Farma Tbk (Kalbe) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle a portfolio of dependable and various brands: the prescription pharmaceutical division, the health products division that handles over-the-counter drugs, multivitamins, and ready-to-serve supplemental drinks, the nutritions division, and the distribution & logistics division. Kalbe has also developed B2B-based digital services ecosystems for the society: EMOS and MOSTRANS. EMOS is an order management application system that helps distribution channels perform their stock or supply chain management actions. MOSTRANS is a B2B transportation solution provider for the easy management and the efficiency of transportation. Kalbe now has more than 40 subsidiaries and 14 international-standard production facilities, supported by around 16,000 employees in 71 branches throughout Indonesia. Kalbe's shares have been listed in Indonesia Stock Exchange/Bursa Efek Indonesia (IDX:KLBF) since 1991. For more information, please visit https://www.kalbe.co.id/ SOURCE GC Cell

Kalbe Frequently Asked Questions (FAQ)

When was Kalbe founded?

Kalbe was founded in 1966.

Where is Kalbe's headquarters?

Kalbe's headquarters is located at Jl. Let. Jend Suprapto Kav 4, Jakarta.

What is Kalbe's latest funding round?

Kalbe's latest funding round is IPO.

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy  here . By continuing to use this site you are consenting to these choices.

Popular Searches

Please try another search.

• Free Sign Up
• English (UK)
• English (India)
• English (Canada)
• English (Australia)
• English (South Africa)
• English (Philippines)
• English (Nigeria)
• Español (España)
• Español (México)
• Português (Portugal)
• Português (Brasil)
• Bahasa Indonesia
• Bahasa Melayu

Kalbe Farma Tbk PT (KLBF)

People Also Watch

Kalbe farma tbk pt news & analysis.

• By Investing.com
• • May 17, 2024
• • May 06, 2024
• • Apr 17, 2024
• • Apr 05, 2024
• • Mar 18, 2024
• • Feb 24, 2024

Kalbe Farma Tbk PT Company Profile

PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products. It operates Mitrasana Clinics, a health care service. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Income Statement

Trending Stocks

• Board of Directors
• Competitive Strengths
• Financial Results
• Financial Highlights
• Annual Reports
• Shareholdings
• Corporate Governance
• Regulatory Disclosure
• Analyst Reports
• Historical Charts

Interactive Charts

• Historical Price
• Stock Fundamentals
• Investment Calculator
• Presentation Slides
• Email Alerts
• All Downloads
• Online Q&A